COVID-19; Interchange of vaccine products; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032H141) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer / BioNTech (Dose Number: 2,Batch/Lot No: EL 9266, Location of injection: Arm Right, Vaccine Administration Time:03:00 PM.) on 02-Feb-2021, Pfizer / BioNTech (Dose Number: 1,Batch/Lot No: EL9264, Location of injection: Arm Left, Vaccine Administration Time:03:00 PM.) on 04-Feb-2021, Erythromycin and Tylenol with codeine. Past adverse reactions to the above products included Allergy with Erythromycin and Tylenol with codeine; and No adverse event with Pfizer / BioNTech and Pfizer / BioNTech. Concurrent medical conditions included Rheumatoid arthritis, Allergic reaction to bee sting (Allergic to bee stings.), Allergy (Allergic to poison ivy) and Sulfonamide allergy. Concomitant products included DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PARACETAMOL, PSEUDOEPHEDRINE HYDROCHLORIDE (DAYQUIL) from 18-May-2022 to 21-May-2022 for Cough, IBUPROFEN (ADVIL [IBUPROFEN]) from 24-May-2022 to 30-May-2022 for Pain, CALCIUM PHOSPHATE, COLECALCIFEROL (VITAFUSION CALCIUM) from 01-May-2022 to an unknown date for an unknown indication.    On 20-Dec-2021 at 2:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 27-May-2022 to 31-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.            Patient had allergy to Sulfa. The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment. The patient had previously received a COVID-19 Vaccine. Patient had a persistent terrible taste in mouth, especially the roof of mouth. More importantly, patient started coughing again (enough to wake up), joint pain, and had nasal congestion on day 4 out of 5 on Paxlovid. Patient had no coughing for two days and nose was fine and also had a little joint pain, which was normal since patient had rheumatoid arthritis. Patient felt really good and was sick again at time of reporting. Device Date : 31-May-2022  Company Comment: This spontaneous case concerns a 45-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious AESI event of COVID-19 unspecified days after receiving the third dose of mRNA-1273 vaccine. Its reported that patient had a persistent terrible taste in mouth, cough, joint pain and nasal congestion on day 4 of Paxlovid treatment. Patient was noted to have received two doses with Pfizer / BioNTech approximately 11 months prior to current vaccination with mRNA-1273 vaccine (Interchange of vaccine products). The current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 45-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious AESI event of COVID-19 unspecified days after receiving the third dose of mRNA-1273 vaccine. Its reported that patient had a persistent terrible taste in mouth, cough, joint pain and nasal congestion on day 4 of Paxlovid treatment. Patient was noted to have received two doses with Pfizer / BioNTech approximately 11 months prior to current vaccination with mRNA-1273 vaccine (Interchange of vaccine products). The current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.